Pancreatic Cancer Research

ResearcherUniversity of Oklahoma Health Sciences CenterActive in the last 2 years

Kritisha Bhandari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4826-207X; OpenAlex author ID A5007550135. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers

Papers 7

  1. Arginine demethylation of Serine/Arginine-rich splicing factor 1 enhances miRNA enrichment in small extracellular vesicles derived from pancreatic ductal adeno… Co-author DOI 10.1096/fj.202401811rr↗
  2. The Level of a Short Form of Multidrug Resistance-Associated Protein 1 Is Elevated in Plasma Small Extracellular Vesicles Derived From Patients With Pancreatic… Co-author DOI 10.1096/fj.202500874r↗
  3. Nuclear Symmetric Dimethylarginine Staining is Indicative of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002509↗
  4. Protein Arginine Methylation Patterns in Plasma Small Extracellular Vesicles Are Altered in Patients with Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16030654↗
  5. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy. Co-author DOI 10.3390/ijms25073958↗
  6. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms24087215↗
  7. Pancreatic Ductal Cell-Derived Extracellular Vesicles Are Effective Drug Carriers to Enhance Paclitaxel's Efficacy in Pancreatic Cancer Cells through Clathrin-… First author DOI 10.3390/ijms23094773↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wei‐Qun Ding · 7 shared papers, 2022–2025 · strength 2.06
  2. Katherine Teresa Morris · 2 shared papers, 2023–2024 · strength 0.52
  3. Michael Anthony Hollingsworth · 1 shared paper, 2025 · strength 0.26
  4. Xiaohui Xu · 1 shared paper, 2023 · strength 0.24
  5. Haoyao Sun · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.